As a Med Honors Top Pharmaceutical Innovator, Gilead Sciences has significantly advanced global health through its pioneering antiviral therapies, particularly in the treatment of HIV, hepatitis, and COVID-19. Founded in 1987, Gilead has become a leader in developing innovative treatments that have transformed once-fatal diseases into manageable chronic conditions.

In the realm of HIV, Gilead's research has been transformative. The company developed the first single-tablet regimen for HIV treatment, simplifying therapy and improving adherence for millions of patients. Their ongoing commitment is evident in the development of lenacapavir, an investigational long-acting injectable that has shown promise in HIV prevention. Recent studies indicate that twice-yearly injections of lenacapavir can offer complete protection from HIV, potentially revolutionizing prevention strategies.

Gilead has also made significant strides in treating hepatitis. The company developed a cure for hepatitis C, and its therapies have helped transform hepatitis B into a more manageable condition.

During the COVID-19 pandemic, Gilead swiftly responded by developing Veklury® (remdesivir), the first approved antiviral treatment for COVID-19. This therapy has been made available to tens of millions of people worldwide and is considered an antiviral standard of care for the treatment of COVID-19, helping both hospitalized and non-hospitalized adult and pediatric patients.

Beyond these therapeutic areas, Gilead is expanding its research into oncology and inflammatory diseases, aiming to bring innovative treatments to patients with unmet medical needs. The company's dedication to scientific excellence and patient-centric innovation underscores its mission to make a lasting impact on global health.

Gilead's unwavering commitment to developing life-changing therapies and ensuring global access solidifies its position as a Med Honors Top Pharmaceutical Innovator.